Qiagen N.V. ranks seventh among the 7 Hot Healthcare Stocks to Buy Right Now. The company, led by CEO Thierry Bernard, specializes in molecular diagnostics and sample preparation technologies. In Q2 2025, Qiagen reported a 7% increase in net sales to $534 million and raised its full-year growth outlook.

Qiagen N.V. launches the QIAseq xHYB Panels for Long-Read Sequencing, enhancing target enrichment for long-read sequencing platforms. The company continues to focus on innovation, expanding its digital and automation offerings while preparing to launch three new instruments by late 2025 to strengthen its molecular diagnostics capabilities.

Despite the potential of Qiagen N.V. as an investment, some believe certain AI stocks offer greater upside potential with less downside risk. For those looking for an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, explore the best short-term AI stock in a free report.

Read more at Yahoo Finance: Qiagen N.V. (QGEN) Launches QIAseq xHYB Panels for Long-Read Sequencing